Today the picture is one of patience being forced on everyone. On MDMA, the drug being studied to treat post-traumatic stress — the deep, lasting fear and pain that follows terrible events — the read is sobering. The trials had a real flaw: many people could tell whether they got the real drug or a fake one, which makes it hard to trust the results. That's not a small paperwork problem, and it likely means the company must run more studies and apply again before approval — maybe not until late 2027. On psilocybin, the active ingredient in magic mushrooms, experts doubt regulators will bless testing it on bipolar disorder — a condition of extreme mood swings — until there are stronger, more careful studies. And on the legal front, a push to loosen federal drug laws is not expected to reach a vote in Congress this year.
Beneath these separate stories runs one thread: the official world moves at the speed of proof, and the human world moves at the speed of need. The rules are being asked to catch up to something already alive on the ground. Notice what the smart money is doing — the companies working on these medicines saw mixed days, and analysts say their stocks won't truly climb until there is a hard yes or no from regulators. That sounds discouraging, but it is actually a sign of a maturing field. The easy hype is draining out. What's left is the slow, real work of proof. The highest path here is not a shortcut. It's the field finally becoming solid enough to hold the weight of millions of people — built once, built right, so it doesn't collapse later.
For the veterans and the families living inside this, the waiting is not abstract. It is a spouse watching someone they love wake up in the dark again. It is a former soldier who has tried everything and heard that the one thing that helped is still years away. This is why underground retreats keep growing — because desperation will not sit quietly in a waiting room. There is real danger there, and someone getting hurt at an unregulated retreat may be what finally forces the rules to move. But there is also a truer thing underneath: people are refusing to be forgotten. The most positive outcome is not the official path or the underground one winning — it is the official world moving fast enough, and the underground world staying safe enough, that the two meet before more people are lost in the gap between them.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
What is forming beneath the surface is always closer than it appears.
75%
Psilocybin for bipolar II needs much stronger safety data first
The US drug regulator (FDA) is very unlikely to approve expanding psilocybin treatment for bipolar II disorder based on the current small, loosely structured studies. Bipolar II involves mood swings that can tip into dangerous highs (called mania), and the FDA needs head-to-head comparison studies before it will sign off. Without that evidence, people with bipolar II won't get access through official medical channels anytime soon.
→ Psilocybin for bipolar II won't get regulatory backing until researchers run proper comparison studies that prove it's safe for people at risk of mania. Confidence: 75%
Resolves: 2027-01-31 · USA
RESEARCH
the precise call ▾
FDA will not endorse bipolar II psilocybin scale-up without controlled comparator data.. The open-label feasibility protocol cannot support efficacy or safety claims in a mood-cycling population with mania risk.
72%
Congress won't vote on making psilocybin legal this year
A bill to change psilocybin's legal status at the federal level is very unlikely to get a full vote in Congress this session. The DEA (the agency that controls which drugs are illegal), the FDA, and most lawmakers aren't aligned enough to push it through. That means psilocybin stays a Schedule I drug federally — the same category as heroin — regardless of what individual states do.
→ Psilocybin will almost certainly remain fully illegal under federal law for at least another year. Confidence: 72%
Resolves: 2027-01-11 · USA
LEGISLATION
the precise call ▾
Federal psilocybin rescheduling will not reach a floor vote this session.. Consensus of 3 agents: legislator, dea_officer, fda_reviewer. 1 dissenting.
72%
Psychedelic company stocks won't see a lasting recovery this year
Stock prices for psychedelic drug companies are unlikely to climb and stay up in 2024 unless one of them publishes strong results from a large late-stage clinical trial or gets a formal decision from the FDA. News about laws or personal healing stories doesn't persuade big institutional investors to move serious money. Only hard clinical proof does.
→ Psychedelic stocks won't recover meaningfully until a company produces a big clinical trial result or wins FDA approval — and neither looks likely this year. Confidence: 72%
Resolves: 2026-12-31 · USA
MARKET
the precise call ▾
No psychedelic biotech will see sustained rally absent a Phase 3 readout or FDA decision this year.. Legislative noise and retreat stories don't move institutional capital. Only de-risked catalysts do, and none are imminent.
70%
Psychedelic company stocks won't see a lasting recovery this year
Stock prices for psychedelic drug companies are unlikely to climb and stay up in 2024 unless one of them publishes strong results from a large late-stage clinical trial or gets a formal decision from the FDA. News about laws or personal healing stories doesn't persuade big institutional investors to move serious money. Only hard clinical proof does.
→ Psychedelic stocks won't recover meaningfully until a company produces a big clinical trial result or wins FDA approval — and neither looks likely this year. Confidence: 70%
Resolves: 2026-08-14 · USA
MARKET
the precise call ▾
No psychedelic biotech sees sustained rally absent a Phase 3 readout or FDA decision this year.. Consensus of 2 agents: investor, journalist. 0 dissenting.
70%
MDMA therapy for PTSD needs a do-over before the FDA will approve it
The FDA (the US drug regulator) is likely to reject the current MDMA-assisted therapy application for PTSD (post-traumatic stress disorder) and ask for a brand new confirmatory study. The core problem is that trial participants could usually tell whether they got MDMA or a placebo, which makes the results unreliable. Even though veterans and others are suffering and dying, the regulator's job is to make sure treatments actually work before allowing them.
→ MDMA therapy for PTSD will almost certainly need an entirely new clinical trial before the FDA approves it, delaying access for people who urgently need it. Confidence: 70%
Resolves: 2027-06-30 · Global
REGULATORY
the precise call ▾
MDMA-PTSD will require a resubmission with new confirmatory data before any approval.. Functional unblinding is a genuine evidentiary flaw, not procedural. My duty is patient protection over urgency, however sympathetic the veteran suicide crisis.